前列腺癌干细胞与去势抵抗性前列腺癌放射性耐受的研究进展  

Research advances in prostate cancer stem cells and radiotherapy resistance of castration-resistant prostate cancer

作　　者：朱逸飞 曾浩[2] 

机构地区：[1]新疆自治区人民医院泌尿中心,乌鲁木齐830001 [2]四川大学华西医院泌尿外科,成都610041

出　　处：《中华放射肿瘤学杂志》2017年第11期1347-1349,共3页Chinese Journal of Radiation Oncology

基　　金：四川省科技厅项目（2015SZ0230）

摘　　要：前列腺癌经过去势治疗后有进展为去势抵抗性前列腺癌的可能。去势抵抗性前列腺癌对临床医生最大的挑战为其治疗抵抗特性。针对放疗耐受,相关研究认为与前列腺癌干细胞及前列腺癌干细胞相关miRNA相关。下文从去势抵抗性前列腺癌进展机制、前列腺癌干细胞及前列腺癌干细胞相关miRNA等方面介绍去势抵抗性前列腺癌放射性耐受的研究进展。Prostate cancer tends to progress to castration-resistant prostate cancer within 24 months after castration. For the management of castration-resistant prostate cancer, the biggest challenge is therapeutic resistance which includes radiotherapy resistance. Relevant studies suggest that the radiotherapy resistance of castration-resistant prostate cancer is associated with prostate cancer stem cells and miRNA related to prostate cancer stem cells. This article reviews the research advances in the radiotherapy resistance of castration-resistant prostate cancer in terms of the possible mechanisms of castration-resistant prostate cancer, prostate cancer stem cells, and miRNA related to prostate cancer stem cells.

关 键 词：去势抵抗性前列腺癌 前列腺癌干细胞 放射性耐受 微小核糖核酸 

分 类 号：R730.55[医药卫生—肿瘤] R737.25[医药卫生—临床医学]